Skip to Main Content
 
Thought Leadership

Hospice and Home Health Moratoria Extension: Strategic and Market Impacts for 2027

 
Podcast

    

On November 12, 2026, CMS announced an extension to the federal hospice and home health moratoria. Bryan Nowicki and Adam Royal are joined by Alex Veach from Agenda Health to discuss the moratoria extension and anticipated impact on valuations and mergers and acquisitions into 2027.

Alex Veach, Partner
Agenda Health
Email: [email protected]

Read the Transcript

This transcript is auto generated

00;00;00;00 - 00;00;29;25

Bryan Nowicki

Hello and welcome to Hospice Insights: The Law and Beyond, where we connect you to what matters in the ever-changing world of hospice and palliative care. Hospice and Home Health Moratoria Extension: Strategic and Market Impacts for 2027. Well, hello Adam. How are you doing? Glad to have you back on the podcast. As everybody knows, Adam, you’re a regular member of our hospice team.

00;00;29;28 - 00;00;34;19

Bryan Nowicki

Head up our transactions and corporate work here at Husch Blackwell.

00;00;34;20 - 00;00;38;03

Adam Royal

Yeah. Hey, Bryan. Thanks for having me back on. Looking forward to being here.

00;00;38;07 - 00;01;03;16

Bryan Nowicki

Great. And I’m particularly excited, we have a guest who’s outside the hospice team, but very much involved in the hospice and home health market. Alex Veach, great to see you again. Great to talk with you. You’re a new name for our listeners. So why don’t you go ahead, introduce yourself. And you’re a part of Agenda Health, which I think is a really great resource for hospices and home health providers out there.

00;01;03;16 - 00;01;06;19

Bryan Nowicki

So will you tell us a bit about Agenda Health as well?

00;01;06;21 - 00;01;29;21

Alex Veach

Sure. Thank you, Bryan, for having me. Excited to join the team here this morning. My name is Alex Veach. I’m a partner at the M&A advisory firm Agenda Health. We are a health care services specialized sell side transaction advisory firm. And so we have been in business for coming up on 20 years here, focused at the start exclusively on geriatric care.

00;01;29;21 - 00;01;37;08

Alex Veach

But more recently, a few other areas, but all still inside of health care services. And so excited for the conversation this morning.

00;01;37;11 - 00;01;59;25

Bryan Nowicki

Great, great. And I think with all that’s been happening in the hospice space in particular over the past year, but as more and more investors get involved in hospice, which has been a year’s long trend, and then stuff like the moratorium and enrollment issues, I think we’ve seen an uptick in a lot of transaction activity or certainly interest in that.

00;01;59;27 - 00;02;11;12

Bryan Nowicki

So very timely for your kind of organizations getting involved more with hospice home health, because I think people are seeing opportunities and they’re both sellers and buyers.

00;02;11;13 - 00;02;28;18

Alex Veach

Yeah, certainly been a very active marketplace over the last 5 or 6 years. We’ve personally overseen over 130 transactions in that six-year window. And so our firm has grown right alongside the marketplace. Excited to talk about the latest news and development here, as it seems to be a new one all the time.

00;02;28;20 - 00;02;49;03

Bryan Nowicki

What exactly. And this is kind of hot off the presses. So we had that moratorium on new enrollments happen earlier this year with a supposed six-month expiration date that was to come up last Friday in the interest of the whole hospice home health community is what’s going to happen with that. And then last Friday, we found out.

00;02;49;03 - 00;03;04;08

Bryan Nowicki

So, Adam, you’ve been on top of that whole process from its inception through will they or won’t they? And then they will. Why don’t you kind of give us the background on that and where we’re left after last Friday.

00;03;04;10 - 00;03;38;04

Adam Royal

Yeah. So last week CMS extended the current moratoria for hospice and home health, which I think was what most of the industry was anticipating they would do. We were certainly anticipating an extension to that. We’ve been under a moratorium since May 13th, 2026, as most of the listeners likely already know by now that moratorium prohibited new enrollments and the addition of new locations for hospice and home health agencies.

00;03;38;08 - 00;04;06;14

Adam Royal

So for a home health agency, that would be a branch office, for hospice, a multiple location. There were a few exceptions in that original moratorium for a change in practice location and changes in provider information. So like a change of information that would be triggered by a stock deal and M&A context and also a change of ownership to be the type of filing triggered by an asset deal in the transactional context.

00;04;06;16 - 00;04;16;05

Adam Royal

So those were the exceptions. Like you said, it was intended to last initially for six months with the ability to extend for additional six-month periods.

00;04;16;11 - 00;04;45;18

Bryan Nowicki

And just to focus on the past six months. With those exceptions, it kind of puts a wet towel over new enrollments like de novo hospices. But the exceptions for changes of information and CHOWs, there’s still transactions that can happen. Did the initial moratorium have any noticeable impact on the market? Was there a change in the increase in transactions during that amount of time?

00;04;45;18 - 00;04;50;08

Bryan Nowicki

And Alex, I welcome you to answer this as well. Do we see anything in that initial six months?

00;04;50;15 - 00;05;15;06

Adam Royal

Yeah, I know with our clients in terms of deal activity, there was an uptick in terms of your ability to grow organically. The two traditional options are either a new enrollment or addition of new locations, and your current enrollment. Both of those were shut down by the moratorium. So the resulting option hospices had to grow was through acquisitions.

00;05;15;06 - 00;05;22;25

Adam Royal

So it seemed like a lot of parties were turning to M&A as a means of growth. That may have been focused more on our organic growth.

00;05;22;27 - 00;05;27;08

Bryan Nowicki

And, Alex, what did you see at Agenda Health? What did you see over these last six months?

00;05;27;10 - 00;05;51;19

Alex Veach

Yeah, I would agree with that. And one that I think is that announcement was announced earlier this year. I think the first thing we got was a little bit of a, hey, let’s wait and see. Right. And let’s see how this evolves over time. See if there are revisions or changes. I think, especially with what they’ve announced in this extension, with the ability to now unfreeze new locations under the same licensure.

00;05;51;26 - 00;06;25;23

Alex Veach

I think that was something that a lot of folks were really looking for. But I would agree with Adam, in general, I think in the last six months, I don’t think there were very many folks in the know that really expected anything other than this extension, Bryan, and so I think there’s a general expectation of that. I think we certainly heard from especially folks on the buy side, hey, you know, regions and markets where we had previously planned to grow into organically via a new licensure application or expansion of our current license, that plan shifted to more of an acquisition driven approach.

00;06;25;26 - 00;06;41;09

Alex Veach

And so certainly have seen not only an uptick in volume, but where there is scarcity of opportunity will eventually create a premium. And I know that’ll be something we talk about later on in the conversation, but that’s something we certainly have our eyes on for 2027.

00;06;41;13 - 00;06;56;06

Bryan Nowicki

All right. So it sounds like this moratorium got people at least thinking about maybe different strategies going forward and the beginnings of some activity. Adam, what happened last week when the moratorium was extended but with some changes?

00;06;56;08 - 00;07;30;12

Adam Royal

Yeah. So it was extended for an additional six months beginning November 12th, 2026. They did scale it back, which was generally good to see. And specifically now they’re allowing additional locations to be added. In the commentary around the extension. They continue to voice concerns around fraudulent actors, especially in the hospice extension, a lot of comments under the general umbrella of hospices admitting ineligible patients to kind of increase their reimbursement.

00;07;30;12 - 00;07;59;18

Adam Royal

And so the focus of CMS now seems to be on actual new hospices and not hospices that are currently enrolled and trying to grow through additional locations. They did identify as their focus now, new hospices paired with kind of some of the language we saw in the initial announcement that they were going to be ramping up all that activity and administrative oversight activities, and for the hospices that are already enrolled.

00;07;59;20 - 00;08;28;29

Bryan Nowicki

Yeah, we certainly saw that. I know in the press release last May, the moratorium was part of a broader effort, and that included increasing data analytics for on the enforcement side. And boy, did they ever do that. And they are continuing to do that. And I think even with the original moratorium, there remains some gray areas, some questions that CMS tried to address through some FAQs or other guidance.

00;08;29;01 - 00;08;36;18

Bryan Nowicki

Has CMS come out with any other interpretive issues, or are they waiting to see what questions arise?

00;08;36;23 - 00;09;02;04

Adam Royal

Yeah, no additional FAQs yet, although I would expect those to either come out, whether that be additional FAQs or revisions to the prior ones. One worth noting is the current exceptions to the moratorium included a change in current practice, location. So as opposed to adding new locations, you would change your current existing location that was excluded from the moratorium.

00;09;02;04 - 00;09;26;07

Adam Royal

But then CMS later came back with the caveat that if a provider makes a substantial change to its existing location, so outside of a current geographic service area, serving a new patient population and using substantially different staff, then they would consider that equivalent to a new enrollment. That was sort of an exception to the exception under the rule.

00;09;26;09 - 00;09;48;07

Adam Royal

With this latest extension, they didn’t clarify how changes to existing locations are going to be treated. So that’s something we’ll have to watch out for. Their general focus on new providers, but sort of seemed to indicate that they would permit changes to primary location. But that’s not necessarily true. So something we’ll want to get clarification from CMS on.

00;09;48;10 - 00;10;13;00

Bryan Nowicki

I know among the alternative CMS had they can shape these moratoria in any number of ways. I think people were talking about is it going to continue, but on a regional level and just hit at certain states or certain regions which they did not do? Did that surprise you, Adam, this approach, as opposed to them adopting other alternatives for the nationwide moratorium, as it was announced last May.

00;10;13;06 - 00;10;47;08

Adam Royal

I don’t think it was necessarily surprising. I think a lot of us were expecting if they did extend it, it would continue to be nationwide. They did, though note in the extension that one of the alternatives they had considered was focusing the moratoria just on Southern California, which, as everyone knows, is a fraud hotspot. A big focus of CMS is fraud enforcement generally, so it would make sense to limit the moratoria to Southern California so it looks like they considered that based on the perception that fraud is still nationwide

00;10;47;13 - 00;10;49;01

Adam Royal

didn’t choose that approach.

00;10;49;04 - 00;11;13;00

Bryan Nowicki

Yeah. I don’t know how Southern California is surviving. They probably only have like a thousand hospices now. So. So where are all the patients going? Southern California has really been the epicenter for a lot of these efforts. And sometimes it feels like CMS is enforcing the whole country as if it were Southern California. But anyway, I won’t get on my soapbox too much.

00;11;13;02 - 00;11;31;26

Bryan Nowicki

Alex, back to you. You kind of told us how the initial six months of the moratorium kind of changed the market, or people’s thinking out there. Now, what do you suspect? What’s your prediction about how this change in the moratorium, what impact is that going to have going forward?

00;11;31;28 - 00;11;56;12

Alex Veach

Yeah, Bryan, I think that’s the million-dollar question, right. Probably more so than that. But I think generally for us, I think you have to draw the distinction within hospice operators in between, I’ll say smaller market opportunities, single site operators, even just acquisitions of licensure as opposed to a scaled agency, because I think at the top end of the market, there’s already been a constraint, right?

00;11;56;12 - 00;12;28;11

Alex Veach

There’s a scarcity in the market as it stands now for scaled, compliant, growing hospice operators. Just with all of the flurry of activity that we saw from 2022 up to 2023, but even in the years since. And so we certainly have seen that for some time now. I think the moratorium is just another log on the fire for premium hospice owners that provide the service the right way to have a history of compliance and strong process around that, and that have exhibited a consistent growth in census.

00;12;28;13 - 00;12;56;22

Alex Veach

And so I think this is just another factor here. As Adam mentioned earlier, I think your private equity backed buyers in the space mostly are growing either organically through additions into their existing license structure, or they’re making acquisitions. Right? And so most groups are going to model for some of both. And so with the restriction on location, add-ons really put a lot more pressure on that lower end of the market for M&A.

00;12;56;25 - 00;13;14;16

Alex Veach

And so I’ll be interested to observe how now that that is allowed for enrolled hospices, what that leads us to. Right? Because I think at the top end of the market there is and I expect will continue to be a very highly engaged platform hospice investor market.

00;13;14;20 - 00;13;36;29

Bryan Nowicki

Yeah, all interesting stuff, Alex. This is great insight that you’re providing. And as the announcement came through last week, was it your sense that there were a lot of hospices just waiting for that announcement and now they’re ready to move forward, or is it still a bit of a wait and see, like how quickly do you think we’re going to see changes if there are going to be any.

00;13;37;02 - 00;13;37;18

Alex Veach

Yeah.

00;13;37;23 - 00;13;58;08

Alex Veach

When we do valuation for probably 5 to 6 hospice agencies every month, just with the breadth of our footprint across the country and the fact that we’ve been focused on the space for almost 20 years now. And so a lot of the owners that I’ve spoken with, certainly it’s among the first questions that we’re asked is what impact has it had?

00;13;58;08 - 00;14;24;14

Alex Veach

And I think historically, our answer has been, hey, if we’re valuing your agency at a 5 to 6X previously, we’re not seeing it now at a 7 to 8. Right? It’s not that linear. But I do think what we have seen is more outreach from some of the buyers in the country that maybe have focused more exclusively on their organic growth opportunities that have now said, hey, I’m back in the game on deals, right?

00;14;24;17 - 00;14;52;25

Alex Veach

I think with this next six months, logically continued strain on the supply of opportunities should drive a more interesting and more fast pace, and eventually a premium for agency owners at all sizes. At the same time, we have to look at other factors as well. Right? Saw an interest rate rise a few weeks back. I think the general expectations is that the fed will increase rates at least 1 or 2 more times over the next few months, and so that has its own impact.

00;14;52;27 - 00;15;09;01

Alex Veach

Generally speaking, I think that what we expect just from our own transactions under management is that there were a lot of folks that were kind of in a wait and see mode. As we start our 2027 slate of deal processes will create a very active environment for hospice add-ons.

00;15;09;03 - 00;15;30;07

Bryan Nowicki

Great, and I’m glad you pointed out interest rates because the moratorium is a big deal. But the market is complex and there’s a lot more out there that is affecting this, even in very significant ways. Let’s say all of this has caused some hospices to consider either selling or buying, and they’re doing that really for the first time.

00;15;30;10 - 00;15;46;12

Bryan Nowicki

What would you suggest they take a look at? How would you give them guidance on what they can expect entering into that kind of a possibility, buying or selling? How do they assess whether it’s right for them, and what do you think they’re going to be expected to do to become part of that process?

00;15;46;14 - 00;16;09;22

Alex Veach

Yeah, that’s a great question. And I think one, we could spend the next half hour on alone, right? I think that process certainly varies from owner to owner. What we tell folks and say you’ve got to start small and go bigger, right? So for every owner they need to start to ask themselves that question. That’s a personal question that I can’t answer for anyone that’s driven by where are you at individually, family circumstances and all of those things.

00;16;09;22 - 00;16;37;24

Alex Veach

Right. And so exempting that side of the equation that is super important, but is more of a personal set of circumstances that has to be evaluated as opposed to a market question. I think we look very specifically by state. Right? So I think the answer there, even though the moratorium is nationally reaching, there are certain states that have state specific restrictions in certain states that are more or less interesting for buyers, especially in scope of the enhanced oversight program.

00;16;37;24 - 00;17;02;07

Alex Veach

And those sorts of things that we look at. We advise owners to be aware, right? And we offer our own structure for that. That includes complimentary valuation and market advice and those things. But paying attention to podcasts like yours and other content that’s out there so that you’re in the know about what’s happening in the market, both in the rearview and staring out the windshield

00;17;02;07 - 00;17;11;10

Alex Veach

here is a responsibility I think owners have so that they know, hey, am I well-placed for this personally? Where’s the business and where’s the market headed so that they can

00;17;11;10 - 00;17;12;13

Alex Veach

make an informed decision.

00;17;12;16 - 00;17;37;11

Bryan Nowicki

Great. Adam, let me bring you back into this because you do a lot of these transactions. I mean, that’s what your focus is from the perspective of an attorney who’s actually working through contracts and due diligence. What can somebody who’s relatively new to that whole process, what should they expect, or what do you want them to know when they’re deciding whether to make the investment, to actually dip their toe in the market and see what is available?

00;17;37;18 - 00;18;04;03

Adam Royal

Yeah, I think the main thing from our perspective in terms of, are you ready to sell or some potential issues that would arise when you get into the transaction context is one, obviously, clinical diligence and audit history. How have you performed? What kind of results have you gotten and audits and have you cleaned those up? Do you have a current robust compliance program that a buyer is going to want to see?

00;18;04;05 - 00;18;32;17

Adam Royal

On the corporate side of things, corporate hygiene is big, especially for smaller hospices. Buyers are going to want to see the corporate governance documents that are in place amended as necessary and accurate, that you have resolutions or consents for activities that were required to be consented to. Bu yeah, the corporate records and documentation are in order and reflect the realities of the organizational structure and operations.

00;18;32;17 - 00;18;56;15

Adam Royal

And then a final one is provider enrollment records. We’re seeing a lot of enforcement activity right now, especially at the CMS level, around provider enrollment records, to ensure that those are up to date and actually reflect the ownership structure. And so if those are out of date, first, that’s a risk of deactivation or even termination for the hospice.

00;18;56;21 - 00;19;20;26

Adam Royal

But it’s also an issue that could cause problems in a transaction context. If the deal documents and the names on those documents don’t reflect the owners that are reported to CMS, when you have to submit those deal documents to CMS, they’re going to see the discrepancy and ask about it. And so getting all of those issues cleaned up in advance would make the due diligence process, transaction process go much more smoothly.

00;19;20;26 - 00;19;25;24

Adam Royal

And I think makes the seller much more valuable target for a potential buyer.

00;19;25;26 - 00;19;45;05

Alex Veach

Bryan, one more thing I was going to throw in there on the clinical side, I think as a part of our process to walk through a high level version of that and a lot of the time we’ll bring in a third party to run a simulated chart audit. Right. And I think that’s something, especially for larger operators, that we advise consistently, just because you don’t really know a lot of the time.

00;19;45;05 - 00;20;14;11

Alex Veach

Right? And it’s small things, right? There are a lot of great groups that do that work. And from a transaction standpoint, I think I see that have a make or break impact on our transactions, so much more so than quality of earnings issues or things like that. Not that those things don’t matter, right? Because it all does. But I think in terms of what makes or breaks deals, where a buyer starts feeling like, okay, there’s liability here that I can’t even really quantify as a result of what my chart audits showed.

00;20;14;11 - 00;20;31;21

Alex Veach

I think that’s where we see real risk. And so there are great groups out there that do that work. We’ll do a high level Q&A-based health check, but for larger operators, if a transaction is on the horizon in the next 2 to 5 years, that chart audit is a great place to start that process.

00;20;31;24 - 00;20;55;29

Bryan Nowicki

Just seeing what Adam gets involved with, with transactions, that’s been my experience is exactly what you have said, Alex. The due diligence part of this, if you want to be in the seller position, you’re going to have to be willing to be very transparent because the potential buyer is going to want to do their due diligence to make sure they’re not getting involved with the provider

00;20;55;29 - 00;20;56;29

Bryan Nowicki

that’s going to have audit

00;20;56;29 - 00;20;58;08

Bryan Nowicki

liability.

00;20;58;10 - 00;21;19;12

Bryan Nowicki

Because audits, they can go back for years. Some other reviews can go back further than that. So the buyer is potentially buying into your history as well. So being prepared to have that transparency is something you got to get comfortable with and plan for. Well, Adam, we’re kind of heading into the new year and not that far from now.

00;21;19;12 - 00;21;30;02

Bryan Nowicki

What are your general expectations relating to the market given the moratorium, given all the other market factors that are out there, what do you expect to happen, Adam.

00;21;30;04 - 00;22;04;25

Adam Royal

Yeah, I’m still expecting an increase in deal activity. We did have a few clients that strategically were waiting to see if the moratorium was extended or not before they decided to buy, and so I expect those types of transactions were out there for a number of people, and we’ll move forward in the coming months. I also think going back to the additional enforcement efforts that CMS is taking while the moratorium is in place, there’s just becoming more and more headwinds for operators to stay in the industry.

00;22;04;27 - 00;22;25;07

Adam Royal

We’ve seen a greater interest in acquisitions on the buy side. On the sell side, more people that may not have been interested in selling a year ago are now interested in selling just because they don’t want to stay in the industry. That seems to be a more and more common story as these efforts go on. So I think that’s driving things from the sell side as well.

00;22;25;07 - 00;22;29;03

Adam Royal

So I think both of those factors kind of point toward an uptick in deals.

00;22;29;06 - 00;22;38;07

Bryan Nowicki

All right. And Alex, same question I want to give you the last word. What are you and what is Agenda Health expecting in this market for 2027?

00;22;38;10 - 00;22;59;00

Alex Veach

Yeah I would agree with Adam. And I certainly think an uptick from the traction we’ve seen this year is in order. I think the one thing we haven’t really talked about that we certainly think will be a factor is the rate increase that was announced recently, 2.3% believe. And so just another factor there for buyers to really get invested and excited about the trend for hospice.

00;22;59;00 - 00;23;19;10

Alex Veach

I think Adam is spot on that it doesn’t seem like CMS is really in all that much of a hurry to make it easier to own and operate a hospice. That’s not a trend we expect to see change anytime soon. I think we’re looking for a higher activity market. I think this first period of the moratorium, we certainly saw a slight increase in activity.

00;23;19;10 - 00;23;45;05

Alex Veach

But I really think as we get into 2027 now that things are a bit more settled and we see the direction that it seems like CMS wants to head in with this, we’ll see. Folks say, okay, this is the new normal and how do we grow our business in spite of this. And so I think it’ll be great environment for hospice owners that have built their agencies the right way, and that are the good actors out there that can really sell a buyer on, hey, I built something special and I built something that you want to have, right?

00;23;45;05 - 00;23;49;01

Alex Veach

That’s growing, that’s compliant, that’s all of those things. And so we’re excited for sure.

00;23;49;07 - 00;24;10;14

Bryan Nowicki

Great. Well, thanks so much, Alex, for joining the podcast. It was wonderful having you on. And we should do this again maybe in 6 or 7 months and kind of check in and see how things have been going. But I appreciate you joining us and in our episode notes for this episode will include Alex’s contact information and that of Agenda Health’s.

00;24;10;16 - 00;24;19;13

Bryan Nowicki

And as always, you folks out there, you know how to contact me or Adam about any questions. And thanks again, Adam, for this timely topic.

00;24;19;16 - 00;24;20;26

Alex Veach

Thanks, Adam. Thanks, Bryan.

00;24;21;03 - 00;24;21;25

Adam Royal

Yeah. Thank you.

00;24;21;29 - 00;24;49;02

Bryan Nowicki

Happy to do it, Alex. Thank you very much. Until next time everybody take care. That’s it for today’s episode of Hospice Insights: The Law and Beyond. Thank you for joining the conversation. To subscribe to our podcast, visit our website at huschblackwell.com or sign up wherever you get your podcasts. Until next time, take care.

Professionals:

Adam L. Royal

Partner